Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3025% above fair value
$232.23−4.75 (-2.00%)
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Core Growth ex-Respiratory: 5.5% in Q3 2026, up 3.0 pts from a year earlier.
Latest, Q3 2026
5.5%
Period ended Sep 30, 2026
Change on a year earlier
+3.0 pts
2.5% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
1
Danaher IR — nongaap_2026Q3
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Measure of core growth across the Danaher ecosystem, excluding the seasonal volatility of Cepheid's respiratory testing business.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Growth ex-Respiratory (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 5.5% | +3.0 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 4.5% | +2.5 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q1 2026 | Mar 31, 2026 | 3.0% | +2.0 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q4 2025 | Dec 31, 2025 | 4.0% | – | Danaher IR — nongaap_2026Q3 ↗ |
| Q3 2025 | Sep 30, 2025 | 2.5% | – | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | 2.0% | – | Danaher IR — nongaap_2026Q3 ↗ |
| Q1 2025 | Mar 31, 2025 | 1.0% | – | Danaher IR — nongaap_2026Q3 ↗ |
Cite this data
StockData. (2026). Danaher Core Growth ex-Respiratory (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/core-sales-growth-ex-resp-total
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.